Cargando…
Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
Immune checkpoint inhibitors (ICIs) have become pivotal in the treatment of lung cancer. An increasing number of immune‐related adverse events (irAEs) have been recognized with their use. To our knowledge, this is the first published case of sarcoid‐like pulmonary lymphadenopathy associated with dur...
Autores principales: | Sanderson, Emma, Wimaleswaran, Hari, Senko, Clare, White, Shane, McDonald, Christine F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040456/ https://www.ncbi.nlm.nih.gov/pubmed/32110415 http://dx.doi.org/10.1002/rcr2.542 |
Ejemplares similares
-
Sarcoid-Like Granulomatosis of the Lung Related to Durvalumab After Chemoradiation for Pulmonary Squamous Cell Carcinoma
por: Minami, Seigo, et al.
Publicado: (2023) -
Sarcoid-Like Mediastinal Lymphadenopathy in Gynecologic Malignancy
por: Lashari, Bilal H., et al.
Publicado: (2018) -
Sarcoid-Like Reactive Lymphadenopathy in Metastatic Synovial Sarcoma
por: Dhillon, Gundip S, et al.
Publicado: (2023) -
Hepatocellular carcinoma with regional lymphadenopathy caused by sarcoid-like reaction: a case report
por: Mizota, Tomoko, et al.
Publicado: (2021) -
Adalimumab induced pulmonary sarcoid reaction
por: Bhargava, S., et al.
Publicado: (2013)